Market Currents
Gilead (GILD -0.9%) slips a bit today after Bristol-Myers (BMY +3.2%) and Abbott (ABT +3.7%)...
-
Monday, October 15, 2012, 1:50 PM ETGilead (GILD -0.9%) slips a bit today after Bristol-Myers (BMY +3.2%) and Abbott (ABT +3.7%) both reported favorable study results for their HCV drugs (I,II). Deutsche Bank defends the stock , saying the results of these studies show that utilizing different drug combinations yields more effective HCV treatments, and that this data actually bodes well for GILD's 7977-based class combos, for which it expects the drug developer to yield similar results.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
